

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
Sheet	1	of	27	Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned 1626
				Examiner Name	To Be Assigned Reitsang Shiao
				Attorney Docket Number	2358.0080002/RWE/RAS

U.S. PATENT DOCUMENTS					
Examiner Initials [*]	Cite No. ¹	Document Number Number-Kind Code ² (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
1.		4,069,343	01/17/1978	Sellstedt <i>et al.</i>	
2.		3,120,551	02/04/1964	Goldschmidt <i>et al.</i>	
3.		3,357,887	12/12/1967	Kagan <i>et al.</i>	
4.		4,069,347	01/17/1978	McCarthy <i>et al.</i>	
5.		4,423,227	12/27/1983	Batz <i>et al.</i>	
6.		4,426,453	01/17/1984	Cree <i>et al.</i>	
7.		4,554,290	11/19/1985	Boger <i>et al.</i>	
8.		4,673,691	06/16/1987	Bachynsky	
9.		4,766,121	08/23/1998	Ellis <i>et al.</i>	
10.		4,826,876	05/02/1989	Ellis <i>et al.</i>	
11.		4,910,305	03/20/1990	Ellis <i>et al.</i>	
12.		5,061,798	10/29/1991	Emmett <i>et al.</i>	
13.		5,116,828	05/26/1992	Miura <i>et al.</i>	
14.		5,158,978	10/27/1992	Rubin	
15.		5,232,946	08/03/1993	Hurnaus <i>et al.</i>	
16.		5,284,971	02/08/1994	Walker <i>et al.</i>	
17.		5,324,522	06/28/1994	Krenning <i>et al.</i>	
18.		5,401,772	03/28/1995	Yokoyama <i>et al.</i>	
19.		5,569,674	10/29/1996	Yokoyama <i>et al.</i>	
20.		5,571,840	11/05/1996	Mayor <i>et al.</i>	
21.		5,627,173	05/06/1997	Graeve <i>et al.</i>	
22.		5,654,468	08/05/1997	Yokoyama <i>et al.</i>	
23.		5,663,159	09/02/1997	Starrett, Jr. <i>et al.</i>	
24.		5,741,803	04/21/1998	Pool <i>et al.</i>	
25.		5,753,254	05/19/1998	Khan <i>et al.</i>	
26.		5,854,282	12/29/1998	Mellin	
27.		5,883,294	03/16/1999	Scanlan <i>et al.</i>	
28.		5,922,775	07/13/1999	Kun <i>et al.</i>	
29.		5,951,989	09/14/1999	Heymann	
30.		6,107,517	08/22/2000	Scanlan <i>et al.</i>	
31.		6,117,873	09/12/2000	Acklin <i>et al.</i>	
32.		6,465,687	10/15/2002	Li <i>et al.</i>	
33.		6,492,424	12/10/2002	Apelqvist <i>et al.</i>	
34.		6,747,048	06/08/2004	Zhang <i>et al.</i>	
35.		7,015,246	03/21/2006	Schmeck <i>et al.</i>	
36.		6,194,454 B1	02/27/2001	Dow	
37.		6,221,911 B1	04/24/2001	Lavin <i>et al.</i>	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	7/27/09
--------------------	-------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ^{}Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [†]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [‡] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [§] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	2	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

38.	6,236,946 B1	05/22/2001	Scanlan <i>et al.</i>	
39.	6,266,622 B1	07/24/2001	Scanlan <i>et al.</i>	
40.	6,326,398 B1	12/04/2001	Chiang <i>et al.</i>	
41.	6,344,481 B1	02/05/2002	Cornelius <i>et al.</i>	
42.	6,361,992 B1	03/26/2002	Szkudlinski <i>et al.</i>	
43.	6,380,255 B1	04/30/2002	Lavin <i>et al.</i>	
44.	6,414,002 B1	07/02/2002	Cheng <i>et al.</i>	
45.	6,414,026 B1	07/02/2002	Billingham	
46.	6,441,015 B1	08/27/2002	Aspnes <i>et al.</i>	
47.	6,465,687 B1	10/15/2002	Li <i>et al.</i>	
48.	6,468,755 B1	10/22/2002	Shoelson	
49.	6,534,676 B2	03/18/2003	Morkin <i>et al.</i>	
50.	6,545,015 B2	04/08/2003	Cheng <i>et al.</i>	
51.	6,545,018 B2	04/08/2003	Chiang <i>et al.</i>	
52.	6,555,582 B1	04/29/2003	Schwartz <i>et al.</i>	
53.	6,566,372 B1	05/20/2003	Zhi <i>et al.</i>	
54.	6,608,049 B2	08/19/2003	Woltering <i>et al.</i>	
55.	6,620,830 B2	09/16/2003	Chiang	
56.	6,664,291 B2	12/16/2003	Chiang <i>et al.</i>	
57.	6,673,815 B2	01/06/2004	Devasthale <i>et al.</i>	
58.	6,680,340 B2	01/20/2004	Cheng <i>et al.</i>	
59.	6,689,896 B2	02/10/2004	Kukkola	
60.	6,716,877 B2	04/06/2004	Morkin	
61.	6,723,744 B2	04/20/2004	Aspnes <i>et al.</i>	
62.	6,727,271 B2	04/27/2004	Cheng <i>et al.</i>	
63.	6,787,652 B2	09/07/2004	Dow <i>et al.</i>	
64.	6,794,406 B2	09/21/2004	Haning <i>et al.</i>	
65.	6,806,381 B2	10/19/2004	Chidambaram <i>et al.</i>	
66.	6,831,102 B2	12/14/2004	Hangeland	
67.	6,852,706 B1	02/08/2005	Heber-Katz	
68.	6,875,782 B2	04/05/2005	Cheng <i>et al.</i>	
69.	6,982,348 B2	01/03/2006	Kori <i>et al.</i>	
70.	7,015,246 B2	03/21/2006	Schmeck <i>et al.</i>	
71.	2004/0097589 A1	05/20/2004	Yi-Lin <i>et al.</i>	
72.	2004/0116387 A1	06/17/2004	Malm <i>et al.</i>	
73.	2004/0220147 A1	11/4/2004	Malm <i>et al.</i>	
74.	2005/0004184 A1	01/6/2005	Ryono <i>et al.</i>	
75.	2001/0051645 A1	12/13/2001	Chiang	
76.	2001/0051657 A1	12/13/2001	Chiang <i>et al.</i>	
77.	2002/0006946 A1	01/17/2002	Aspnes <i>et al.</i>	

Examiner Signature	/Rei Tsang Shiao/	Date Considered
--------------------	-------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
Sheet	3	of	27	Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
				Attorney Docket Number	2358.0080002/RWE/RAS

78.	2002/0045751 A1	04/18/2002	Kukkola		
79.	2002/0049226 A1	04/25/2002	Chiang <i>et al.</i>		
80.	2002/0107390 A1	08/08/2002	Kukkola		
81.	2002/0123521 A1	09/05/2002	Lavin		
82.	2003/0027862 A1	02/06/2003	Haning <i>et al.</i>		
83.	2003/0040535 A1	02/27/2003	Aspnes <i>et al.</i>		
84.	2003/0078288 A1	04/24/2003	Haning <i>et al.</i>		
85.	2003/0078289 A1	04/24/2003	Aspnes <i>et al.</i>		
86.	2003/0114521 A1	06/19/2003	Chiang <i>et al.</i>		
87.	2003/0153513 A1	08/14/2003	Shiomi <i>et al.</i>		
88.	2003/0166724 A1	09/04/2003	Hangeland		
89.	2004/0029187 A1	02/12/2004	Palmer		
90.	2004/0039028 A1	02/26/2004	Zhang <i>et al.</i>		
91.	2004/0077694 A1	04/22/2004	Chiang <i>et al.</i>		
92.	2004/0110951 A1	06/10/2004	Chiang		
93.	2004/0116391 A1	06/17/2004	Piccariello <i>et al.</i>		
94.	2004/0142868 A1	07/22/2004	Sleeman		
95.	2004/0152783 A1	08/05/2004	Olon <i>et al.</i>		
96.	2004/0157844 A1	08/12/2004	Dow <i>et al.</i>		
97.	2004/0219218 A1	11/04/2004	Martino <i>et al.</i>		
98.	2005/0038122 A1	02/17/2005	Hangeland		
99.	2005/0054727 A1	03/10/2005	Hangeland		
100.	2005/0085541 A1	04/21/2005	Shiohara <i>et al.</i>		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document <small>Country Code² Number⁴ Kind Code⁵ (if known)</small>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
	101.	WO 89/08458 A1	09/21/1989	Univ. of Delaware; Cogburn	
	102.	WO 90/08155 A1	07/26/1990	Board of Regents, The Univ. of Texas System; Farquhar	
	103.	WO 90/10636 A1	09/20/1990	Board of Regents, The Univ. of Texas System; Farquhar	
	104.	WO 91/06569 A1	05/16/1991	Boots Pharmaceuticals Inc.	
	105.	WO 91/11181 A1	08/08/1991	British Techonology Group (USA) Inc.; Rubin	
	106.	WO 95/00135 A1	01/05/1995	The Regents of the Univ. of Michigan; Mayor <i>et al.</i>	
	107.	WO 95/24919 A1	09/21/1995	K.U. Leuven Research & Development; Var Den Berghe <i>et al.</i>	
	108.	WO 96/05190 A1	02/22/1996	Karo Bio AB; Mellin	
	109.	WO 96/40048 A2	12/19/1996	Karo Bio AB; Lavin <i>et al.</i>	

Examiner Signature	/Rei Tsang Shiao/	Date Considered
--------------------	-------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
Sheet	4	of	27	Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
				Attorney Docket Number	2358.0080002/RWE/RAS

110.	WO 97/21993 A2	06/19/1997	The Regents of the Univ. of California; Scanlan <i>et al.</i>
111.	WO 98/07435 A1	02/26/1998	The Regents of the Univ. of California; Schwartz <i>et al.</i>
112.	WO 98/41216 A1	09/24/1998	Tam <i>et al.</i>
113.	WO 98/57919 A1	12/23/1998	The Regents of the Univ. of California; Scanlan <i>et al.</i>
114.	WO 99/00353 A1	01/07/1999	Karo Bio AB; Li <i>et al.</i>
115.	WO 99/26966 A2	06/03/1999	The Regents of the Univ. of California; Scanlan <i>et al.</i>
116.	WO 99/29321 A1	06/17/1999	The Chancellor, Masters and Scholars of the Univ. of Oxford; Thomas Jefferson University; Block <i>et al.</i>
117.	WO 99/38376 A1	08/05/1999	Univ. of Maryland; Univ. of Arkansas; Kuenzel <i>et al.</i>
118.	WO 99/45016 A1	09/10/1999	Metabasis Therapeutics, Inc.; Erion <i>et al.</i>
119.	WO 99/62507 A1	12/09/1999	Arthromics PLC; Billingham <i>et al.</i>
120.	WO 00/00468 A1	01/06/2000	The Regents of the Univ. of California; Scanlan <i>et al.</i>
121.	WO 00/07972 A1	02/17/2000	Karo Bio AB; Apelqvist <i>et al.</i>
122.	WO 00/39077 A2	07/06/2000	Karo Bio AB; Hangeland <i>et al.</i>
123.	WO 00/51971 A1	09/08/2000	Pfizer Products Inc.; Chiang <i>et al.</i>
124.	WO 00/52015 A1	09/08/2000	Metabasis Therapeutics, Inc.; Erion <i>et al.</i>
125.	WO 00/58279 A1	10/05/2000	Novartis-Erfindungen; Kukkola
126.	WO 01/13936 A1	03/01/2001	Schwartz <i>et al.</i>
127.	WO 01/18013 A1	03/15/2001	Metabasis Therapeutics, Inc.; Erion <i>et al.</i>
128.	WO 01/36365 A2	05/25/2001	Karo Bio AB; Malm <i>et al.</i>
129.	WO 01/60784 A1	08/23/2001	Bristol-Myers Squibb Co.; Friends <i>et al.</i>
130.	WO 01/72692 A1	10/04/2001	Pfizer Products Inc.; Aspnes <i>et al.</i>
131.	WO 01/94293 A2	12/13/2001	Bristol-Myers Squibb Co.; Ryono
132.	WO 01/98256 A1	12/27/2001	Karo Bio AB; Yi-Lin <i>et al.</i>
133.	WO 02/03914 A2	01/17/2002	Delsys Pharmaceutical Corp.; Murari <i>et al.</i>
134.	WO 02/04515 A1	01/17/2002	BTG International Limited; Jones <i>et al.</i>
135.	WO 02/05834 A2	01/24/2002	Karo Bio AB; Lavin
136.	WO 02/11666 A2	02/14/2002	D-Pharm Ltd.; Kozark <i>et al.</i>
137.	WO 02/26752 A1	04/04/2002	Ilex Oncology Research S.A.; Phan <i>et al.</i>
138.	WO 02/32408 A2	04/25/2002	Novartis AG; Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.; Steele <i>et al.</i>
139.	WO 02/060374 A2	08/08/2002	Insight Strategy & Marketing; Ayal-Hershkovitz
140.	WO 02/062780 A2	08/15/2002	Karo Bio AB; Malm <i>et al.</i>
141.	WO 02/066017 A1	08/29/2002	Abbott Laboratories; Ritter <i>et al.</i>
142.	WO 02/072528 A1	09/19/2002	Eli Lilly and Company; Ligand Pharmaceuticals Inc.; Bell <i>et al.</i>
143.	WO 02/092550 A1	11/21/2002	Karo Bio AB; Malm <i>et al.</i>

Examiner Signature	/Rei Tsang Shiao/	Date Considered
--------------------	-------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). ¹See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ²Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	5	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

144.	WO 03/003013 A1	01/09/2003	Univ. of Massachusetts; Leonard <i>et al.</i>
145.	WO 03/015771 A1	02/27/2003	Lion Bioscience AG; Bauer <i>et al.</i>
146.	WO 03/018515 A2	03/06/2003	Karo Bio AB; Malm <i>et al.</i>
147.	WO 03/039456 A2	05/15/2003	Bristol-Myers Squibb Co.; Chidambaram <i>et al.</i>
148.	WO 03/061557 A2	07/31/2003	King Pharmaceuticals, Inc.; Franz <i>et al.</i>
149.	WO 03/061567 A2	07/31/2003	Merck & co., Inc.; Doherty <i>et al.</i>
150.	WO 03/070169 A2	08/28/2003	Ilex Products, Inc.; Phan <i>et al.</i>
151.	WO 03/075835 A2	09/18/2003	Smithline Beecham Corp.; Maglich <i>et al.</i>
152.	WO 03/084915 A1	10/16/2003	Karo Bio AB; Rahimi-Ghadim <i>et al.</i>
153.	WO 03/094845 A2	11/20/2003	Bristol-Myers Squibb Co.; Zhang <i>et al.</i>
154.	WO 03/099864 A1	12/04/2003	Stichting Tot Devordering Van De Wetenschap Der Endocrinologie; Friesema <i>et al.</i>
155.	WO 03/105760 A2	12/24/2003	Enteromed, Inc.; Wolfe <i>et al.</i>
156.	WO 04/007430 A2	01/22/2004	Karo Bio AB; Bristol-Myers Squibb Co., Garg <i>et al.</i>
157.	WO 04/014318 A2	02/19/2004	King Pharmaceuticals, Inc.; Strauss <i>et al.</i>
158.	WO 04/018421 A1	03/04/2004	Karo Bio AB; Malm <i>et al.</i>
159.	WO 04/026097 A2	04/01/2004	First Circle Medical, Inc.; Vam Hattum <i>et al.</i>
160.	WO 04/041208 A2	05/21/2004	New River Pharmac. Inc.; Olon <i>et al.</i>
161.	WO 04/065620 A2	08/05/2004	Isis Pharmaceuticals Inc.; Bennett <i>et al.</i>
162.	WO 04/066929 A2	08/12/2004	Bristol-Myers Squibb Co.; Washburn <i>et al.</i>
163.	WO 04/067482 A2	08/12/2004	Bristol-Myers Squibb Co.; Washburn <i>et al.</i>
164.	WO 04/078947 A2	09/16/2004	ZymoGenetics Inc.; Kelly
165.	WO 04/091636 A1	10/28/2004	Vital Health Sciences; West <i>et al.</i>
166.	WO 04/093799 A2	11/04/2004	Bristol-Myers Squibb Co.; Ryono <i>et al.</i>
167.	WO 04/103289 A2	12/02/2004	New York University, Molsoft LLC; Samuels <i>et al.</i>
168.	WO 05/009433 A1	02/03/2005	Goglia <i>et al.</i>
169.	WO 05/016862 A1	02/24/2005	Asahi Kasei Pharma Corp.; Shoda <i>et al.</i>
170.	WO 05/021895 A2	03/31/2005	Ordway Research Institute; Mousa <i>et al.</i>
171.	WO 05/028488 A1	03/31/2005	Quatrax Pharma Co.; Bridges
172.	WO 05/042556 A1	05/12/2005	Genelabs Technologies, Inc.; Keicher <i>et al.</i>
173.	WO 05/123729 A1	12/29/2005	Metabasis Therapeutics, Inc.; Martin
174.	WO 06/128055 A2	11/30/2006	Metabasis Therapeutics, Inc.; Erion <i>et al.</i>
175.	WO 06/128056 A2	11/30/2006	Metabasis Therapeutics, Inc.; Erion <i>et al.</i>
176.	WO 06/128058 A2	11/30/2006	Metabasis Therapeutics, Inc.; Erion <i>et al.</i>
177.	WO 07/009913 A1	01/25/2007	F. Hoffmann-La Roche AG; Haynes <i>et al.</i>
178.	EP 1 666 035 A1	06/07/2006	Chugai Seikaku Kabushiki Kaisha
179.	EP 1 471 049 A1	10/27/2004	Kissei Pharma. Co., Ltd.

Examiner Signature	/Rei Tsang Shiao/	Date Considered
--------------------	-------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet 6 of 27				Attorney Docket Number	2358.0080002/RWE/RAS

	180.	EP 1 297 833 A1	04/02/2003	Pfizer Products Inc.	
	181.	EP 0 580 550 A1	01/26/1994	Ciba-Giegy AG	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
	182.	Amma, L.L., <i>et al.</i> , "Distinct Tissue-Specific Roles for Thyroid Hormone Receptors β and α 1 in Regulation of Type 1 Deiodinase Expression," <i>Mol. Endocrinol.</i> 15:467-475, The Endocrine Society (2001)	
	183.	Anderson, S.N., <i>et al.</i> , "Activation of Electrophilic Aromatic Substitution by the Substituent -CH ₂ Co(dmgH) ₂ py. Products of Reaction of Benzylcobaloximes with Halogens in Acetic Acid," <i>J. Chem. Soc. Perkin Trans. II</i> 311-318, Royal Society of Chemistry (1972)	
	184.	Annett, R.G., <i>et al.</i> , "Enzymatically catalysed decarboxylation of β -carboxyaspartic acid (Asa)," <i>Can. J. Chem.</i> 68:886-887, NRC Research Press (1990)	
	185.	Antons, K.A., <i>et al.</i> , "Clinical Perspectives of Statin-Induced Rhabdomyolysis," <i>Am. J. Med.</i> 119:400-409, Excerpta Medica (May 2006)	
	186.	Apriletti, J.W., <i>et al.</i> , "Molecular and Structural Biology of Thyroid Hormone Receptors," <i>Clin. Exp. Pharmacol. Physiol.</i> 25:S2-S11, Blackwell Science Asia (1998)	
	187.	Archer, S.J., <i>et al.</i> , "Hepatitis C Virus NS3 Protease Requires Its NS4A Cofactor Peptide for Optimal Binding of a Boronic Acid Inhibitor as Shown by NMR," <i>Chem. Biol.</i> 9:79-92, Elsevier Science Ltd. (January 2002)	
	188.	Arnold, S., <i>et al.</i> , "3,5-Diiodothyronine binds to subunit Va of cytochrome-c oxidase and abolishes the allosteric inhibition of respiration by ATP," <i>Eur. J. Biochem.</i> 252:325-330, Blackwell Science Ltd. (1998)	
	189.	Arnold, L.A., <i>et al.</i> , "Discovery of Small Molecule Inhibitors of the Interaction of the Thyroid Hormone Receptor with Transcriptional Coregulators," <i>J. Biol. Chem.</i> 280:43048-43055, American Society for Biochemistry and Molecular Biology (December 2005)	
	190.	Auerbach, B.J., <i>et al.</i> , "Comparative Effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: Atorvastatin versus Lovastatin," <i>Atherosclerosis</i> 115:173-180, Elsevier Science Ltd. (1995)	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	7	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

191.	Auberson, Y.P., <i>et al.</i> , "N-Phosphonoalkyl-5-Aminomethylquinoxaline-2,3-Diones: <i>In Vivo</i> Active AMPA and NMDA (Glycine) Antagonists," <i>Bioorg. Med. Chem. Lett.</i> 9:249-254, Elsevier Science Ltd. (1999)	
192.	Ayajiki, K., <i>et al.</i> , "Endothelial and Neuronal Functions in Cerebral and Temporal Arteries from Monkeys Fed a High Cholesterol Diet," <i>J. Cardiovascular Pharmacol.</i> 40:456-466, Lippincott Williams & Wilkins (September 2002)	
193.	Ball, S.G., <i>et al.</i> , "3,5-Diiodo-L-thyronine (T ₂) has selective thyromimetic effects <i>in vivo</i> and <i>in vitro</i> ," <i>J. Mol. Endocrinol.</i> 19:137-147, Society for Endocrinology (1997)	
194.	Baxter, J.D., <i>et al.</i> , "Structure-Based Design and Synthesis of a Thyroid Hormone Receptor (TR) Antagonist," <i>Endocrinology</i> 143:517-524, Endocrine Society (February 2002)	
195.	Baxter, J.D., <i>et al.</i> , "Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight," <i>Trends Endocrinol. Metab.</i> 15:154-157, Elsevier Science Ltd. (May/June 2004)	
196.	Beg, M.A.A. and Clark, H.C., "Chemistry of the Trifluoromethyl Group, Part III. Phenyltrifluoromethylphosphine and Related Compounds," <i>Can. J. Chem.</i> 39:564-570, NRC Research Press (1962)	
197.	Beg, M.A.A. and Clark, H.C., "Chemistry of the Trifluoromethyl Group, Part IV. Diphenyltrifluoromethylphosphine and Complex Formation by Phenyltrifluoromethylphosphines," <i>Can. J. Chem.</i> 40:283-288, NRC Research Press (1962)	
198.	Benayoud, F. and Hammond, G.B., "An expedient synthesis of (α,α-difluoroprop-2-ynyl) phosphonate esters," <i>Chem. Commun.</i> 1447-1448, Royal Society of Chemistry (1996)	
199.	Bianco, A.C., <i>et al.</i> , "Biochemistry, Cellular and Molecular Biology, and Physiological Roles of the Iodothyronine Selenodeiodinases," <i>Endocrine Rev.</i> 23:38-89, The Endocrine Society (February 2002)	
200.	Bilger, C., <i>et al.</i> , "A Convenient One-Pot Synthesis of Aralkyl Bromides and Iodides by Reductive Halogenation of Aromatic Carbonyl Compounds," <i>Synthesis</i> 902-904, Georg Thieme Verlag (1988)	
201.	Blennemann, B., <i>et al.</i> , "Tissue-Specific Regulation of Fatty Acid Synthesis by Thyroid Hormone," <i>Endocrinology</i> 130:637-643, The Endocrine Society (1992)	
202.	Bobyleva, V., <i>et al.</i> , "Decrease in mitochondrial energy coupling by thyroid hormones: a physiological effect rather than a pathological hyperthyroidism	

Examiner Signature	/Rei Tsang Shiao/	Date Considered
--------------------	-------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
Sheet	8	of	27	Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
				Attorney Docket Number	2358.0080002/RWE/RAS

		consequence," <i>FEBS Lett.</i> 430:409-413, Elsevier Science Ltd. (1998)	
	203.	Bocan, T.M.A., <i>et al.</i> , "HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit," <i>Atherosclerosis</i> 139:21-30, Elsevier Science Ltd. (1998)	
	204.	Bogardus, J.B. and Higuchi, T., "Kinetics and Mechanism of Hydrolysis of Labile Quaternary Ammonium Derivatives of Tertiary Amines," <i>J. Pharm. Sci.</i> 71:729-735, Wiley (1982)	
	205.	Bohmer, V. and Vogt, W., "7.(<i>o</i> -Hydroxyphenyl)methylphosphonic acids: Synthesis and Potentiometric Determination of their pKa Values," <i>Helvetica Chimica Acta</i> 76:139-149, Verlag Helvetica Chimica Acta (1993)	
	206.	Boyd, E.A., <i>et al.</i> , "Facile Synthesis of Functionalised Phenylphosphinic Acid Derivatives," <i>Tetrahedron Lett.</i> 37:1651-1654, Elsevier Science Ltd. (1996)	
	207.	Boyd, E.A. and Regan, A.C., "Synthesis of γ -Keto-substituted Phosphinic Acids from Bis(trimethylsilyl)phosphonite and α,β -Unsaturated Ketones," <i>Tetrahedron Lett.</i> 33:813-816, Elsevier Science Ltd. (1992)	
	208.	Briel, D., <i>et al.</i> , "3-Amino-5-phenoxythiophenes: Syntheses and Structure-Function Studies of a Novel Class of Inhibitors of Cellular L-Triiodothyronine Uptake," <i>J. Med. Chem.</i> 42:1849-1854, American Chemical Society (1999)	
	209.	Brown, K., <i>et al.</i> , "Accelerator Mass Spectrometry for Biomedical Research," <i>Meth. Enzymol.</i> 402:423-443, Academic Press (November 2005)	
	210.	Christian, M.S. and Trenton, N.A., "Evaluation of thyroid function in neonatal and adult rats: The neglected endocrine mode of action," <i>Pure Appl. Chem.</i> 75:2055-2068, International Union of Pure and Applied Chemistry (November 2003)	
	211.	Cimmino, M., <i>et al.</i> , "Demonstration of in vivo metabolic effects of 3,5-di-iodothyronine," <i>J. Endocrinol.</i> 149:319-325, Society for Endocrinology (1996)	
	212.	Clutterbuck, P.W. and Cohen, J.B., "The Aryl and Alkyl Sulphonamides," <i>J. Chem. Soc.</i> 123:2507-2515, Royal Society of Chemistry (1923)	
	213.	Collazo, A-M.G., <i>et al.</i> , "Thyroid receptor ligands. Part 5: Novel bicyclic agonist ligands selective for the thyroid hormone receptor β ," <i>Bioorg. Med. Chem. Lett.</i> 16:1240-1244, Elsevier Science Ltd. (March 2006)	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known			
				Application Number		10/580,134	
				Int'l Filing Date		November 19, 2004	
				First Named Inventor		ERION, Mark D.	
				Art Unit		To Be Assigned	
				Examiner Name		To Be Assigned	
Sheet	9	of	27	Attorney Docket Number	2358.0080002/RWE/RAS		

214.	Columbano, A., <i>et al.</i> , "The Thyroid Hormone Receptor-β Agonist GC-1 Induces Cell Proliferation in Rat Liver and Pancreas," <i>Endocrinology</i> 147:3211-3218, Endocrine Society (March 2006)	
215.	Corrie, J.E.T. and Trentham, D.R., "Synthetic, Mechanistic and Photochemical Studies of Phosphate Esters of Substituted Benzoins," <i>J. Chem. Soc. Perkin Trans. 1</i> : 2409-2417, Chemical Society (1992)	
216.	Crimmins, M.T., <i>et al.</i> , "Asymmetric Aldol Additions: Use of Titanium Tetrachloride and (-)-Sparteine for the Soft Enolization of <i>N</i> -Acyl Oxazolidinones, Oxazolidinethiones, and Thiazolidinethiones," <i>J. Org. Chem.</i> 66:894-902, American Chemical Society (2001)	
217.	Croxall, W.J., <i>et al.</i> , "Organic Reactions with Boron Fluoride. XI. The Condensation of Propylene with <i>m</i> -and <i>p</i> -Hydroxybenzoic acids," <i>J. Am. Chem. Soc.</i> 57:1549-1551, American Chemical Society (1935)	
218.	Danzi, S., <i>et al.</i> , "Triiodothyronine-mediated myosin heavy chain gene transcription in the heart," <i>Am. J. Physiol. Heart Circ. Physiol.</i> 284:H2255-H2262, The American Physiological Society (2003)	
219.	Database Beilstein (Online). Beilstein Registry Number: 7222862, 6 pages, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE	
220.	Database Beilstein (Online). Beilstein Registry Number: 7505261, 2 pages, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE	
221.	Database Beilstein (Online). Beilstein Registry Number: 6636402, 4 pages, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE	
222.	Database CAplus, Chemical Abstract Service, Columbus Ohio, Enrion, M.D., <i>et al.</i> , "Preparation of phosphonic acid-containing liver-selective thyromimetics effective against metabolic diseases," WO 2005-0512986, 16 pages (created June 2005)	
223.	Davis, R. and Untch, K.G., "Direct one-step Conversion of Alcohols into Nitriles," <i>J. Org. Chem.</i> 46:2985-2987, American Chemical Society (1981)	
224.	Davis, P.J., <i>et al.</i> , "Comparison of the mechanisms of nongenomic actions of thyroid hormone and steroid hormones," <i>J. Endocrinol. Invest.</i> 25: 377-388, Italian Society of Endocrinology (April 2002)	
225.	De Brabandere, V.I., <i>et al.</i> , "Isotope Dilution-Liquid Chromatography/Electrospray Ionization-Tandem Mass Spectrometry for the Determination of Serum Thyroxine as a Potential Reference Method," <i>Rapid</i>	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
				Intl' Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	<i>To Be Assigned</i>
				Examiner Name	<i>To Be Assigned</i>
Sheet	10	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

		<i>Commun. Mass Spectrometry 12:1099-1103, Wiley (1998)</i>	
	226.	De Sandro, V., <i>et al.</i> , "Comparison of the Effects of Propylthiouracil, Amiodarone, Diphenylhydantoin, Phenobarbital, and 3-Methylcholanthrene on Hepatic and Renal T4 Metabolism and Thyroid Gland Function in Rats," <i>Toxicol. Appl. Pharmacol. 111:263-278</i> , Academic Press (1991)	
	227.	Demori, I., <i>et al.</i> , "3,-5-diiodothyronine Mimics the Effect of Triiodothyronine on Insulin-like growth Factor Binding Protein-4 Expression in Cultured Rat Hepatocytes," <i>Horm. Metab. Res. 36:679-685</i> , Georg Thieme Verlag (October 2004)	
	228.	Depréle, S. and Montchamp, J.-L., "A novel and convenient preparation of hypophosphite esters," <i>J. Organometallic Chem. 643-644:154-163</i> , Elsevier Science Ltd. (August 2002)	
	229.	Dhawan, B. and Redmore, D., "1,2-Alkanediol Bis(Dihydrogen Phosphates)," <i>Synth. Commun. 18:327-331</i> , Georg Thieme Verlag (1988)	
	230.	Dingwall, J.G., <i>et al.</i> , "Dithoxymethylphosphonites and Phospinates. Intermediates for the Synthesis of α,β -and γ -Aminoalkylphosphonous Acids," <i>Tetrahedron 45:3787-3808</i> , Pergamon Press (1989)	
	231.	DiStefano III, J.J. and Feng, D., "Comparative Aspects of the Distribution, Metabolism, and Excretion of Six Iodothyronines in the Rat," <i>Endocrinology 123:2514-2525</i> , Endocrine Society (1988)	
	232.	Docter, R., <i>et al.</i> , "Inhibition of Uptake of Thyroid Hormone into Rat Hepatocytes by Preincubation with <i>N</i> -Bromoacetyl-3,3',5-Triiodothyronine," <i>Endocrinology 123:1520-1525</i> , The Endocrine Society (1988)	
	233.	Dow, R.L., <i>et al.</i> , "Discovery of a Novel Series of 6-Azauracil-Based Thyroid Hormone Receptor Ligands: Potent, TR β Subtype-Selective Thyromimetics," <i>Bioorg. Med. Chem. Lett. 13:379-382</i> , Elsevier Science Ltd. (November 2003)	
	234.	Drechsler, U. and Hanack, M., "An Easy Route from Catechols to Phthalonitriles," <i>Synlett 1207-1208</i> , Georg Thieme Verlag (1998)	
	235.	Earle, M.J., <i>et al.</i> , "The first high yield green route to a pharmaceutical in a room temperature ionic liquid," <i>Green Chem. 2:261-262</i> , Royal Society of Chemistry (2000)	
	236.	Ebdrup, S., <i>et al.</i> , "Structure-activity relationship for aryl and heteroaryl boronic acid inhibitors of hormone-sensitive lipase," <i>Bioorg. Med. Chem. 13:2305-2312</i> , Elsevier Science Ltd. (January 2005)	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
Sheet	11	of	27	Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
				Attorney Docket Number	2358.0080002/RWE/RAS

237.	Edwards, M.L., <i>et al.</i> , "Difluoromethylidiphenylphosphine oxide. A new reagent for conversion of carbonyl compounds to 1,1-difluoroolefins," <i>Tetrahedron Lett.</i> 31:5571-5574, Elsevier Science Ltd. (1990)	
238.	Eisch, J.J., <i>et al.</i> , "Rearrangement and Cleavage of [(Aryloxy)methyl]silanes by Organolithium Reagents: Conversion of Phenols into Benzylic Alcohols," <i>J. Org. Chem.</i> 47:5051-5056, American Chemical Society (1982)	
239.	Ekins, R., "Validity of Analog Free Thyroxin Immunoassays" <i>Clin. Chem.</i> 33:2137-2152, American Association For Clinical Chemistry (1987)	
240.	Erion, M.D., <i>et al.</i> , "Design, Synthesis, and Characterization of a Series of Cytochrome P ₄₅₀ 3A-Activated Prodrugs (HepDirect Prodrugs) Useful for Targeting Phosph(on)ate-Based Drugs to the Liver," <i>J. Am. Chem. Soc.</i> 126:5154-5163, American Chemical Society (April 2004)	
241.	Erion, M.D., <i>et al.</i> , "Liver-Targeted Drug Delivery Using HepDirect Prodrugs," <i>J. Pharmacol. Exper. Ther.</i> 312:554-560, American Society for Pharmacology and Experimental Therapeutics (February 2005)	
242.	Fabiano, E., <i>et al.</i> , "A Simple Conversion of Alcohols into Amines," <i>Synthesis</i> 190-192, Georg Thieme Verlag (1987)	
243.	Faergemann, J., <i>et al.</i> , "Dose-Response Effects of Tri-iodothyroacetic Acid (Triac) and other Thyroid Hormone Analogues on Glucocorticoid-Induced Skin Atrophy in the Haired Mouse," <i>Acta Derm. Venereol.</i> 82:179-183, Society for the Publication of Acta Dermato-Venereologica (March 2002)	
244.	Farquhar, D., <i>et al.</i> , "Biologically-Cleavable Phosphate Protective Groups: 4-Acyloxy-1,3,2-Dioxaphosphorinanes as Neutral Latent Precursors of Dianionic Phosphates," <i>Tetrahedron Lett.</i> 36:655-658, Elsevier Science Ltd. (1995)	
245.	Feinstein, S., <i>et al.</i> , "Subacute Atheromatous Lesions in Monkey and Man", <i>Clin. Cardiol.</i> 6:109-115, John Wiley & Sons, Inc. (1983)	
246.	Feng, W., <i>et al.</i> , "Hormone-Dependent Coactivator Binding to a Hydrophobic Cleft on Nuclear Receptors," <i>Science</i> 280:1747-1749, American Association for the Advancement of Science (1998)	
247.	Field, L.D. and Wilkinson, M.P., "A new Synthesis of 1,2-Bis(Bis(Trifluoromethyl)Phosphino)ethane," <i>Tetrahedron Lett.</i> 33:7601-7604, Elsevier Science Ltd. (1992)	
248.	Fieser, L.F. and Arda, M.I., "Investigation of the Chemical Nature of Gonyleptidine," <i>J. Am. Chem. Soc.</i> 78:774-781, American Chemical Society (1956)	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	12	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

249.	Fleischmann, K., <i>et al.</i> , "Synthesis of HR 916 B: The First Technically Feasible Route to the 1-(Pivaloyloxy)ethyl Esters of Cephalosporins," <i>Liebigs Ann.</i> 1735-1741, Verlag Chemie (1996)	
250.	Fong, T.-L., <i>et al.</i> , "Hyperthyroidism and Hepatic Dysfunction," <i>J. Clin. Gastroenterol.</i> 14:240-244, Raven Press (1992)	
251.	Freitas, F.R.S., <i>et al.</i> , "Spared bone mass in rats treated with thyroid hormone receptor TR β -selective compound GC-1," <i>Am. J. Physiol. Endocrinol. Metab.</i> 285:E1135-E1141, American Physiological Society (September 2003)	
252.	Freitas, F.R.S., <i>et al.</i> , "The Thyroid Hormone Receptor β -Specific Agonist GC-1 Selectivity Affects the Bone Development of Hypothyroid Rats," <i>J. Bone Mineral Res.</i> 20:294-304, American Society for Bone and Mineral Research (November 2004)	
253.	Froestl, W., <i>et al.</i> , "Phosphinic Acid Analogues of GABA. 1. "New Potent and Selective GABA _B Agonists," <i>J. Med. Chem.</i> 38:3297-3312, American Chemical Society (1995)	
254.	Froestl, W., <i>et al.</i> , "Phosphinic Acid Analogues of GABA. 2. Selective, Orally Active GABA _B Antagonists," <i>J. Med. Chem.</i> 38:3313-3331, American Chemical Society (1995)	
255.	Gallagher, M.J. and Honegger, H., "Organophosphorus Intermediates. VI. The Acid-Catalysed Reaction of Trialkyl Orthoformates with Phosphinic Acid," <i>Aust. J. Chem.</i> 33:287-294, Commonwealth Scientific And Industrial Research Organization (1980)	
256.	Gilman, H. and Calloway, N.O., "Super-Aromatic Properties of Furan. II. The Friedel-Crafts Reaction," <i>J. Am. Chem. Soc.</i> 55:4197-4205, American Chemical Society (1933)	
257.	Goglia, F., <i>et al.</i> , "In Vitro binding of 3,5-di-iodo-L-thyronine to rat liver mitochondria," <i>J. Mol. Endocrinol.</i> 13: 275-282, Society for Endocrinology (1994)	
258.	Goglia, F., "Biological Effects of 3,5-Diiodothyronine (T ₂)," <i>Biochemistry (Moscow)</i> 70:164-172, Pleiades Publishing, Inc. (February 2005)	
259.	Goglia, F., <i>et al.</i> , "Interaction of diiodothyronines with isolated cytochrome c oxidase," <i>FEBS Lett.</i> 346:295-298, Elsevier Science Ltd. (1994)	
260.	Goodrich, P., <i>et al.</i> , "Kinetic Study of the Metal Triflate Catalyzed Benzoylation of Anisole in an Ionic Liquid," <i>Ind. Eng. Chem. Res.</i> 45:6640-6647, American Chemical Society (September 2006)	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	13	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

261.	Goswami, A., <i>et al.</i> , "Inhibition by coumadin anticoagulants of enzymatic outer ring monodeiodination of iodothyronines," <i>Biochem. Biophys. Res. Commun.</i> 104:1231-1238, Academic Press (1982)
262.	Goya, R.G., <i>et al.</i> , "Effects of Growth Hormone and Thyroxine on Thymulin Secretion in Aging Rats," <i>Neuroendocrinology</i> 58:338-343, S. Karger AG, Basel (1993)
263.	Greco, M.N., <i>et al.</i> , "Discovery of Potent, Selective, Orally Active, Nonpeptide Inhibitors of Human Mast Cell Chymase," <i>J. Med. Chem.</i> 50:1727-1730, American Chemical Society (March 2007)
264.	Gregory, R.B. and Berry, M.N., "On the thyroid hormone-induced increase in respiratory capacity of isolated rat hepatocytes," <i>Biochim. Biophys. Acta</i> 1098:61-67, Elsevier Science Ltd. (1991)
265.	Gronemeyer, H., <i>et al.</i> , "Principles for Modulation of the Nuclear Receptor Superfamily" <i>Nature Reviews, Drug Discovery</i> 3:950-964, Nature Publishing Group (November 2004)
266.	Grover, G.J., <i>et al.</i> , "Development of the Thyroid Homone Receptor β -Subtype Agonist KB-141: A Strategy for Body Weight Reduction and Lipid Lowering with Minimal Cardiac Side Effects," <i>Cardiovascular Drug Rev.</i> 23:133-148, Blackwell Publishing (November 2005)
267.	Grover, G.J., <i>et al.</i> , "Selective thyroid hormone receptor- β activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability," <i>PNAS</i> 100:10067-10072, National Academy of Sciences (August 2003)
268.	Guernik, S., <i>et al.</i> , "A novel system consisting of Rh-DuPHOS and ionic liquid for asymmetric hydrogenations," <i>Chem. Commun.</i> 2314-2315, Royal Society of Chemistry (2001)
269.	Hadváry, P. and Weller, T., "202. Conformationally Restricted Analogs of Platelet-Activating Factor (PAF)," <i>Helvetica Chimica Acta</i> 69:1862-1871, Verlag Helvetica Chimica Acta (1986)
270.	Hashimoto, A., <i>et al.</i> , "Design and synthesis of complementing ligands for mutant thyroid hormone receptor TR β (R320H): a tailor-made approach toward the treatment of resistance to thyroid hormone," <i>Bioorg. Med. Chem.</i> 13:3627-3639, Elsevier Science Ltd. (June 2005)
271.	Hayakawa, Y., <i>et al.</i> , "A General Approach to Nucleoside 3'- and 5'-Monophosphates," <i>Tetrahedron Lett.</i> 28:2259-2262, Elsevier Science Ltd. (1987)

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	14	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

272.	Hedfors, Å., <i>et al.</i> , "Thyroid Receptor Ligands. 3. Design and Synthesis of 3,5-Dihalo-4-alkoxyphenylalkanoic Acids as Indirect Antagonists of the Thyroid Hormone Receptor," <i>J. Med. Chem.</i> 48:3114-3117, American Chemical Society (May 2005)
273.	Heimberg, M., <i>et al.</i> , "Plasma Lipoproteins and Regulation of Hepatic Metabolism of Fatty Acids in Altered Thyroid States," <i>Endocrine Rev.</i> 6:590-607, Endocrine Society (1985)
274.	Hennemann, G., <i>et al.</i> , "Carrier-Mediated Transport of Thyroid Hormone into Rat Hepatocytes is Rate-Limiting in Total Cellular Uptake and Metabolism," <i>Endocrinology</i> 119:1870-1872, Endocrine Society (1986)
275.	Hennemann, G., "Notes on the History of Cellular Uptake and Deiodination of Thyroid Hormone," <i>Thyroid</i> 15:753-756, Mary Ann Liebert Publishers (August 2005)
276.	Holý, A., "Phosphonomethoxyalkyl Analogs of Nucleotides," <i>Curr. Pharm. Des.</i> 9:2567-2592, Bentham Science Publishers (December 2003)
277.	Horst, C., <i>et al.</i> , "3,5-Di-iodo-L-thyronine suppresses TSH in rats <i>in vivo</i> and in rat pituitary fragments <i>in vitro</i> ," <i>J. Endocrinol.</i> 145:291-297, Society for Endocrinology (1995)
278.	Horst, C., <i>et al.</i> , "Rapid Stimulation of hepatic oxygen consumption by 3,5-di-iodo-L-thyronine," <i>Biochem. J.</i> 261:945-950, Portland Press (1989)
279.	Howarth, J., <i>et al.</i> , "Sodium Borohydride Reduction of Aldehydes and Ketones in the Recyclable Ionic Liquid [BMIM]PF ₆ ," <i>Synth. Commun.</i> 31:2935-2938, Taylor & Francis (2001)
280.	Huddleston, J.G., <i>et al.</i> , "Characterization and comparison of hydrophilic and hydrophobic room temperature ionic liquids incorporating the imidazolium cation," <i>Green Chem.</i> 3:156-164, Royal Society of Chemistry (2001)
281.	Hum, G., <i>et al.</i> , "Synthesis of [Difluoro-(3-alkenylphenyl)-methyl]-phosphonic Acids on Non-crosslinked Polystyrene and Their Evaluation as Inhibitors of PTP1B," <i>Bioorg. Med. Chem. Lett.</i> 12:3471-3474, Elsevier Science Ltd. (August 2002)
282.	Hume, J.R., <i>et al.</i> , "Anion Transport in Heart," <i>Physiol. Rev.</i> 80:31-81, The American Physiological Society (2000)
283.	Hunter, D.H., <i>et al.</i> , "Crown ether catalysis of decarboxylation and decarbalkoxylation of β-keto acids and malonates: a synthetic application," <i>Can. J. Chem.</i> 58:2271-2277, NRC Research Press (1980)

Examiner Signature	/Rei Tsang Shiao/	Date Considered
--------------------	-------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	15	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

284.	Ichikawa, K., <i>et al.</i> , "Mechanism of liver-selective thyromimetic activity of SK&F L-94901: evidence for the presence of a cell-type-specific nuclear iodothyronine transport process," <i>J. Endocrinol.</i> 165:391-397, Society for Endocrinology (2000)	
285.	Ing, H.R., "The Pharmacology of Homologous Series," <i>Fortschritte der Arzneimittelforschung. Progress in drug research. Progrès des recherches pharmaceutiques</i> 20:306-309, Birkhäuser Verlag (1964)	
286.	Iyer, S. and Liebeskind, L.S., "Regiospecific Synthesis of 2-Methoxy-3-methyl-1,4-benzoquinones from Maleoylcobalt Complexes and Alkynes via Lewis Acid Catalysis. A Highly Convergent Route to Isoquinoline Quinones," <i>J. Am. Chem. Soc.</i> 109:2759-2770, American Chemical Society (1987)	
287.	Jepson, E.M., "Thyroxine analogues as hypocholesterolemic agents," <i>Am. Heart J.</i> 67:422-424, Mosby (1964)	
288.	Johnson, E.O., <i>et al.</i> , "Experimentally-induced hyperthyroidism is associated with activation of the rat hypothalamic-pituitary-adrenal axis," <i>Eur. J. Endocrinol.</i> 153:177-185, BioScientifica Ltd (July 2005)	
289.	Jones, P.B. and Porter, N.A., "2-Aroylbenzoyl Serine Proteases: Photoreversible Inhibition or Photoaffinity Labeling?", <i>J. Am. Chem. Soc.</i> 121:2753-2761, American Chemical Society (1999)	
290.	Jorgensen, E.C., "Thyroid Hormones and Analogs. II. Structure-Activity Relationships," in: <i>Hormonal Proteins and Peptides</i> , Li, C.H., eds., Academic Press, New York, NY, pp. 107-204 (1978)	
291.	Jorgensen, E.C., "Thyroid Hormones and Analogs. I. Synthesis, Physical Properties and Theoretical Calculations," in: <i>Hormonal Proteins and Peptides</i> , Li, C.H., eds., Academic Press, New York, NY, pp. 56-105 (1978)	
292.	Jorgensen, E.C. and Murray, W.J., "Thyroxine Analogs. 22. Thyromimetic Activity of Halogen-Free Derivatives of 3,5-Dimethyl-L-Thyronine," <i>J. Med. Chem.</i> 17:434-439 (1974)	
293.	Kadenbach, B., <i>et al.</i> , "Mitochondrial Energy Metabolism is Regulated via Nuclear-Coded Subunits of Cytochrome C Oxidase," <i>Free Radical Biol. Med.</i> 29:211-221, Elsevier Science Ltd. (2000)	
294.	Kazemifard, A.G., <i>et al.</i> , "Identification and quantitation of sodium-thyroxine and its degradation products by LC using electrochemical and MS detection," <i>J. Pharm. Biomed. Anal.</i> 25:697-711, Elsevier Science Ltd. (2001)	
295.	Kennedy, J.A., <i>et al.</i> , "Influence of Imipramine on the Hypothalamic/Pituitary/Thyroid Axis of the Rat," <i>Metabolism</i> 46:1429-1434, W.B. Saunders (1997)	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	16	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

296.	Kennedy, J.F., <i>et al.</i> , "Isolation of thyroxine-binding globulin (TBG) by immunoaffinity chromatography: some physical and immunochemical characteristics of TBG," <i>Clinica Chimica Acta</i> 129:251-261, Elsevier Science Ltd. (1983)	
297.	Knölker, H.-J. and Filali, S., "Transition Metal Complexes in Organic Synthesis, Part 69. Total Synthesis of the <i>Amaryllidaceae</i> Alkaloids Anhydrolycorinone and Hippadine Using Iron-and Palladium-Mediated Coupling Reactions," <i>Synlett</i> 1752-1754, Georg Thieme Verlag (June 2003)	
298.	Kobayashi, H., <i>et al.</i> , "Organization of Nucleosides Supported by Boronic-Acid-Appended Poly(L-lysine): Creation of a Novel RNA Mimic," <i>Bull. Chem. Soc. Jpn.</i> 74:1311-1317, The Chemical Society of Japan (2001)	
299.	Koehler, K., <i>et al.</i> , "Thyroid Receptor Ligands. 6. A High Affinity "Direct Antagonist" Selective for the Thyroid Hormone Receptor," <i>J. Med. Chem.</i> 49:6635-6637, American Chemical Society (October 2006)	
300.	Koerner, D., <i>et al.</i> , "Binding of Selected Iodothyronine Analogues to Receptor Sites of Isolated Rat Hepatic Nuclei," <i>J. Biol. Chem.</i> 250:6417-6423, American Society for Biochemistry and Molecular Biology (1975)	
301.	Krause, B.R., <i>et al.</i> , "Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats," <i>Atherosclerosis</i> 127:91-101, Elsevier Science Ltd. (1996)	
302.	Kvetny, J., "3,5-T ₂ Stimulates Oxygen Consumption, But Not Glucose Uptake in Human Mononuclear Blood Cells," <i>Horm. Metab. Res.</i> 24:322-325, Georg Thieme Verlag (1992)	
303.	Lacoste, A.M., <i>et al.</i> , "Research Regarding Aminoalkylphosphonic Acids. II. - Iodine Derivatives of the Phosphonic Analog of Tyrosine," <i>Bull. Soc. Chim. Biol.</i> 49:1827-1835, Masson Et Cie (1967)	
304.	Lacoste, A.-M., <i>et al.</i> , "Biochemistry - Synthesis and biological properties of the phosphonic analog of thyroxine," <i>C. R. Acad. Sci. Paris</i> 267:1890-1892, Gauthier Villars Editeur (1968)	
305.	Lacoste, A.-M., <i>et al.</i> , "Endocrinology. Action of the phosphonic analog of thyroxine on post-embryonic development of the tadpole of <i>Rana dalmatina</i> Bon," <i>Biol. Soc. Bordeaux</i> 1684-1689 (1967)	
306.	Lanni, A., <i>et al.</i> , "Specific Binding sites for 3,3'-diiodo-L-thyronine (3,3'-T ₂) in rat liver mitochondria," <i>FEBS Lett.</i> 351:237-240, Elsevier Science Ltd. (1994)	
307.	Lanni, A., <i>et al.</i> , "Effect of 3,3'-di-iodothyronine and 3,5-di-iodothyronine on rat liver mitochondria," <i>J. Endocrinol.</i> 136:59-64, Society for Endocrinology (1993)	

Examiner Signature	/Rei Tsang Shiao/	Date Considered
--------------------	-------------------	-----------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	17	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

308.	Lanni, A., <i>et al.</i> , "Effect of 3,3'-diiodothyronine and 3,5-diiodothyronine on rat liver oxidative capacity," <i>Mol. Cell. Endocrinol.</i> 86:143-148, Elsevier Scientific Publishers Ireland (1992)	
309.	Lanni, A., <i>et al.</i> , "Rapid stimulation in vitro of rat liver cytochrome oxidase activity by 3,5-diiodo-L-thyronine and by 3,3'-diiodo-L-thyronine," <i>Mol. Cell. Endocrinol.</i> 99:89-94, Elsevier Science Ltd. (1994)	
310.	Lanni, A., <i>et al.</i> , "Expression of uncoupling protein-3 and mitochondrial activity in the transition from hypothyroid to hyperthyroid state in rat skeletal muscle," <i>FEBS Lett.</i> 444:250-254, Elsevier Science Ltd. (1999)	
311.	Lanni, A., <i>et al.</i> , "Calorigenic effect of diiodothyronines in the rat," <i>J. Physiol.</i> 494:831-837, Blackwell Publishing (1996)	
312.	Laskorin, B.N., <i>et al.</i> , "Preparation and Investigation of the Steric Structure of Sterically Hindered α -oxo Phosphoryl Compounds," <i>Zhurnal Obshchei Khimii</i> 44:1716-1720, Rossiiskaya Akademiya Nauk (1974)	
313.	Lee, S.-G., <i>et al.</i> , "Microwave-assisted Kabachnik-Fields Reaction in Ionic Liquid," <i>Bull. Korean Chem. Soc.</i> 23:667-668, The Korean Chemical Society (March 2002)	
314.	Lee, Y.-P., <i>et al.</i> , "Effects of Thyroid Hormones on the Guinea Pig," <i>Endocrinology</i> 86:241-250, The Endocrine Society (1970)	
315.	Leonard, J.L. and Rosenberg, I.N., "Iodothyronine 5'-Deiodinase from Rat Kidney: Substrate Specificity and the 5'-Deiodination of Reverse Triiodothyronine," <i>Endocrinology</i> 107:1376-1383, The Endocrine Society (1980)	
316.	Leonard, J.L. and Rosenberg, I.N., "Thyroxine 5'-Deiodinase Activity of Rat Kidney: Observations on Activation by Thiols and Inhibition by Propylthiouracil," <i>Endocrinology</i> 103:2137-2144, The Endocrine Society (1978)	
317.	Lewis, D.S., "Effects of dietary cholesterol on adipose tissue lipoprotein lipase in the baboon," <i>Biochim. Biophys. Acta</i> 879:44-50, Elsevier Science Ltd. (1986)	
318.	Li, Y.-L., <i>et al.</i> , "Thyroid receptor ligands. Part 4: 4'-amido bioisosteric ligands selective for the thyroid hormone receptor beta," <i>Bioorg. Med. Chem. Lett.</i> 16:884-886, Elsevier Science Ltd. (February 2006)	
319.	Liddle, C., <i>et al.</i> , "Separate and Interactive Regulation of Cytochrome P450 3A4 by Triiodothyronine, Dexamethasone, and Growth Hormone in Cultured Hepatocytes," <i>J. Clin. Endocrinol. Metab.</i> 83:2411-2416, The Endocrine Society (1998)	

Examiner Signature	/Rei Tsang Shiao/	Date Considered
--------------------	-------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
Sheet	18	of	27	Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
				Attorney Docket Number	2358.0080002/RWE/RAS

320.	Lin, C.-C., <i>et al.</i> , "Pharmacokinetics of Pradefovir and PMEA in Healthy Volunteers After Oral Dosing of Pradefovir," <i>J. Clin. Pharmacol.</i> 45:1250-1258, Sage Science Press (November 2005)	
321.	Linsel-Nitschke, P. and Tall, A.R., "HDL as a Target in the Treatment of Atherosclerotic Cardiovascular Disease," <i>Nature Reviews, Drug Discovery</i> 4:193-205, Nature Publishing Group (March 2005)	
322.	Liotta, D., <i>et al.</i> , "A Simple, Inexpensive Procedure for the Large-Scale Production of Alkyl Quinones," <i>J. Org. Chem.</i> 48:2932-2933, American Chemical Society (1983)	
323.	Lombardi, A., <i>et al.</i> , "Characterization of the binding of 3, 3'-di-iodo-L-thyronine to rat liver mitochondria," <i>J. Endocrinol.</i> 154:119-124, Society for Endocrinology (1997)	
324.	Lombardi, A., <i>et al.</i> , "Effect of 3,5-di-iodo-L-thyronine on the mitochondrial energy-transduction apparatus," <i>Biochem. J.</i> 330:521-526, Portland Press (1998)	
325.	Lukashev, N.V., <i>et al.</i> , "Palladium-Catalyzed Cross-Coupling Reactions of Organocopper Derivatives of Methylphosphonic Esters and Amides with Aryl and Hetaryl Iodides," <i>Russian J. Gen. Chem.</i> 71:172-178, Kluwer Academic Publishers (2001)	
326.	Mackenzie, P.I., <i>et al.</i> , "Regulation of UDP Glucuronosyltransferase Genes," <i>Curr. Drug Metab.</i> 4:249-257, Bentham Science Publishers (June 2003)	
327.	Mains, R.E. and Eipper, B.A., "Tissue Culture of Primary Rat Anterior Pituitary Cells" in <i>Regulatory Peptides: From Molecular Biology to Function</i> , Costa, E., Trabucchi, M., eds., Raven Press, New York City, NY, pp. 1-8 (1982)	
328.	Makinen, M.W. and Lee, C.-P., "Biochemical Studies of Skeletal Muscle Mitochondria: I. Microanalysis of Cytochrome Content, Oxidative and Phosphorylative Activities of Mammalian Skeletal Muscle Mitochondria," <i>Arch. Biochem. Biophys.</i> 126:75-82, Academic Press (1968)	
329.	Malevannaya, R.A., <i>et al.</i> , "(Dialkoxyphosphinyl) Acetic Acids and Some of Their Analogs," <i>Zhurnal Obshchey Khimii</i> 41:1426-1434, Rossiiskaya Akademiya Nauk (1971)	
330.	Marcune, B.F., <i>et al.</i> , "Selective displacement of aryl fluorides with hydroquinone: synthesis of 4-phenoxyphenols" <i>Tetrahedron Lett.</i> 46:7823-7826, Elsevier Science Ltd. (November 2005)	
331.	Marimuthu, A., <i>et al.</i> , "TR Surfaces and Conformations Required to Bind Nuclear Receptor Corepressor" <i>Mol. Endocrinol.</i> 16:271-286, The Endocrine Society (February 2002)	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	19	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

332.	Matsui, T., <i>et al.</i> , "Discovery of Novel Phosphonic Acid Derivatives as New Chemical Leads for Inhibitors of TNF- α Production," <i>Bioorg. Med. Chem.</i> 10:3807-3815, Elsevier Science Ltd. (August 2002)	
333.	McClain, R.M., "Mechanistic considerations for the relevance of animal data on thyroid neoplasia to human risk assessment," <i>Mutation Res.</i> 333:131-142, Elsevier Science Ltd. (1995)	
334.	Mertins, K., <i>et al.</i> , "Transition-Metal-Catalyzed Benzylation of Arenes and Heteroarenes," <i>Angew. Chem. Int. Ed.</i> 44:238-242, Wiley-VCH Verlag GmbH & Co. (December 2004)	
335.	Middleton, W.J., "New Fluorinating Reagents. Dialkylaminosulfur Fluorides," <i>J. Org. Chem.</i> 40:574-578, American Chemical Society (1975)	
336.	Miyabara, E.H., <i>et al.</i> , "Thyroid hormone receptor- β -selective agonist GC-24 spares skeletal muscle type I to II fiber shift," <i>Cell Tissue Res.</i> 321:233-241, Springer-Verlag (August 2005)	
337.	Mocchegiani, E., <i>et al.</i> , "Neuroendocrine-thymus interactions. I. <i>In vitro</i> modulation of thymic factor secretion by thyroid hormones," <i>J. Endocrinol. Invest.</i> 13:139-147, Italian Society of Endocrinology (1990)	
338.	Moreno, M., <i>et al.</i> , "How the thyroid controls metabolism in the rat: different roles for triiodothyronine and diiodothyronines," <i>J. Physiol.</i> 505:529-538, Cambridge Univ. Press (1997)	
339.	Morkin, E., <i>et al.</i> , "Pilot Studies on the Use of 3, 5-Diiodothyropropionic Acid, a Thyroid Hormone Analog, in the Treatment of Congestive Heart Failure," <i>Cardiology</i> 97:218-225, S. Karger AG, Basel (July 2002)	
340.	Moscioni, A.D. and Gartner, L.M., "Thyroid Hormone and Hepatic UDP-Glucuronosyl Transferase Activity: Contrary Effects in Rat and Mouse," <i>Res. Commun. Chem. Pathol. Pharmacol.</i> 39:445-462, Pjd Publications Ltd. (1983)	
341.	Murphy-Jolly, M.B., <i>et al.</i> , "The synthesis of tris(perfluoroalkyl)phosphines," <i>Chem. Commun.</i> 4479-4480, Royal Society of Chemistry (August 2005)	
342.	Nabeshima, T., <i>et al.</i> , "Rate-accelerating Metal Ion Effects on Decarboxylation of α -Keto Acids by a Thiazolium Ion bearing a Metal Binding Site," <i>J. Chem. Soc. Chem. Commun.</i> 373-374, Royal Society of Chemistry (1991)	
343.	Ness, G.C., <i>et al.</i> , "Effects of L-Triiodothyronine and the Thyromimetic L-94901 on Serum Lipoprotein Levels and Hepatic Low-Density Lipoprotein Receptor, 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase, and Apo A-I Gene Expression," <i>Biochem. Pharmacol.</i> 56:121-129, Elsevier Science Ltd. (1998)	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
Sheet	20	of	27	Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
				Attorney Docket Number	2358.0080002/RWE/RAS

344.	Nguyen, N.-H., <i>et al.</i> , "Hammett Analysis of Selective Thyroid Hormone Receptor Modulators Reveals Structural and Electronic Requirements for Hormone Antagonists," <i>J. Am. Chem. Soc.</i> 127:4599-4608, American Chemical Society (March 2005)	
345.	Nishinaga, <i>et al.</i> , "Model Reactions for the Biosynthesis of Thyroxine. XII. The Nature of a Thyroxine Precursor Formed in the Synthesis of Thyroxine from Diiodotyrosine and Its Keto Acid Analog," <i>Biochemistry</i> 7:388-397, American Chemical Society (1968)	
346.	Nurtdinov, S.Kh., <i>et al.</i> , "Reactions of Alkylphosphonous Dichlorides with Carboxylic Acid Chlorides," <i>Zhurnal Obshchey Khimii</i> 41:2486-2490, Rossiiskaya Akademiya Nauk (1971)	
347.	Ocasio, Cory A., and Scanlan, T.S., "Clinical prospects for new thyroid hormone analogues" <i>Curr. Opin. Endocrinol. Diabetes</i> 12:363-370, Lippincott Williams & Wilkins (October 2005)	
348.	Ocasio, Cory A., and Scanlan, T.S., "Design and characterization of a thyroid hormone receptor α (TR α)-Specific Agonist," <i>ACS Chem. Biol.</i> 1:585-593, American Chemical Society (October 2006)	
349.	O'Reilly, Ian, and Murphy, M.P., "Studies on the rapid stimulation of mitochondrial respiration by thyroid hormones." <i>Acta Endocrinol.</i> 127:542-546, Romanian Society for Endocrinology (1992)	
350.	O'Reilly, Ian, and Murphy, M.P., "Treatment of hypothyroid rats with T ₂ (3,5-di-iodo-L-thyronine) rapidly stimulates respiration in subsequently isolated mitochondria," <i>Biochem. Soc. Trans.</i> 20:59S, Portland Press (1991)	
351.	Osuka, A., <i>et al.</i> , "Synthesis of Arenephosphonates by Copper(I) Iodide-Promoted Arylation of Phosphite Anions," <i>Synthesis</i> 69-71, George Thieme Verlag- Stuttgart (1983)	
352.	Pan, S.-Y., <i>et al.</i> , "Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice," <i>Eur. J. Pharmacol.</i> 552:170-175 Elsevier Science Ltd. (December 2006)	
353.	Panne, P., <i>et al.</i> , "Cyanide initiated perfluoroorganylations with perfluoroorgano silicon compounds" <i>J. Fluorine Chem.</i> 112:283-286 Elsevier Science Ltd. (2001)	
354.	Pétervári, E., <i>et al.</i> , "Hyperphagia of hyperthyroidism: Is neuropeptide Y involved?" <i>Regulatory Peptides</i> 131:103-110, Elsevier Science Ltd. (November 2005)	
355.	Prashad, M., "Phosphonate vs. Phosphinate Elimination during Olefination of Aldehydes," <i>Tetrahedron Lett.</i> 34:1585-1588, Elsevier Science Ltd. (1993)	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	21	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

356.	Psarra, A.-M.G., <i>et al.</i> , "The mitochondrion as a primary site of action of steroid and thyroid hormones: Presence and action of steroid and thyroid hormone receptors in mitochondria of animal cells." <i>Mol. Cell. Endocrinol.</i> 246:21-33, Elsevier Science Ltd. (February 2006)	
357.	Pue, M.A., <i>et al.</i> , "The disposition of SK&F L-94901, a selective thyromimetic in rat, dog and cynomolgus monkey," <i>Eur. J. Drug Metab. Pharmacokinetics</i> 14:209-219, Edition Medecine Et Hygiene (1989)	
358.	Radominska-Pandya, A., <i>et al.</i> , "A Historical Overview of the Heterologous Expression of Mammalian UDP-Glucuronosyltransferase Isoforms Over the Past Twenty Years," <i>Curr. Drug Metab.</i> 6:141-160, Bentham Science Publishers Ltd. (April 2005)	
359.	Rai, R., and Katzenellenbogen, J.A., "Effect of Conformational Mobility and Hydrogen-Bonding Interactions on the Selectivity of Some Guanidinoaryl-Substituted Mechanism-Based Inhibitors of Trypsin-like Serine Proteases," <i>J. Med. Chem.</i> 35:4297-4305, American Chemical Society (1992)	
360.	Rashid, S., <i>et al.</i> , "Effect of Atorvastatin on High-Density Lipoprotein Apolipoprotein A-I Production and Clearance in the New Zealand White Rabbit," <i>Circulation</i> 106:2955-2960, Lippincott Williams & Wilkins (December 2002)	
361.	Razumov, A.I. and Gazizov, M.B., "Reactivity of Organophosphorus Carbonyl-Containing Compounds IV. Synthesis, Properties, and Structure of Acylphosphinic Esters," <i>Zhurnal Obshchey Khimii</i> 37:2738-2742, Rossiiskaya Akademiya Nauk (1967)	
362.	Ren, S.G., <i>et al.</i> , "Dose-Response Relationship Between Thyroid Hormone and Growth Velocity in Cynomolgus Monkeys," <i>J. Clin. Endocrinol. Metab.</i> 66:1010-1013, The Endocrine Society (1988)	
363.	Ribeiro, R.C.J., <i>et al.</i> , "X-ray Crystallographic and Functional Studies of Thyroid Hormone Receptor," <i>J. Steroid Biochem. Molec. Biol.</i> 65:133-141, Pergamon Press (1998)	
364.	Rooda, S.J.E., <i>et al.</i> , "Metabolism of Triiodothyronine in Rat Hepatocytes," <i>Endocrinology</i> 125:2187-2197, The Endocrine Society (1989)	
365.	Ross, J. and Xiao, J., "Friedel-Crafts acylation reactions using metal triflates in ionic liquid," <i>Green Chem.</i> 4:129-133, Royal Society of Chemistry (February 2002)	
366.	Ruhlandt-Senge, K. and Englich, U., "Synthesis and characterization of the first discrete potassium thiolates displaying three different coordination spheres at potassium in one molecule," <i>Chem. Commun.</i> 147-148, Royal Society of	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	22	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

		Chemistry (1996)	
	367.	Saitoh, H. and Aungst, B.J., "Improvement of the Intestinal Absorption of a Peptidomimetic, Boronic Acid Thrombin Inhibitor Possibly Utilizing the Oligopeptide Transporter," <i>Pharm. Res.</i> 16:1786-1789, Plenum Publishing Corporation (1999)	
	368.	Sakamoto, T., <i>et al.</i> , "Cross-Coupling of N-Heteroaryl Halides with Active Methylene Compounds in the Presence of Tetrakis(triphenylphosphine)palladium," <i>Chem. Pharm. Bull.</i> 36:1664-1668, Pharmaceutical Society of Japan (1988)	
	369.	Sakamoto, T., <i>et al.</i> , "Palladium-Catalyzed Condensation of Aryl Halides with Phenylsulfonylacetoneitrile and Diethyl Cyanomethylphosphonate," <i>Chem. Pharm. Bull.</i> 38:1513-1517, Pharmaceutical Society of Japan (1990)	
	370.	Samuels, H.H., <i>et al.</i> , "Depletion of L-3,5,3'-Triiodothyronine and L-Thyroxine in Euthyroid Calf Serum for Use in Cell Culture Studies of the Action of Thyroid Hormone," <i>Endocrinology</i> 105:80-85, The Endocrine Society (1979)	
	371.	Sano, M. and Yamatera, H., "Potential Energy Surface of $[\text{Cu}(\text{H}_2\text{O})_6]^{2+}$ and $[\text{Zn}(\text{H}_2\text{O})_6]^{2+}$ Derived From Ab Initio MO Calculations," <i>Chem. Lett.</i> 1495-1496, The Chemical Society of Japan (1980)	
	372.	Sass, D.A., <i>et al.</i> , "Nonalcoholic Fatty Liver Disease: A Clinical Review," <i>Dig. Dis. Sci.</i> 50:171-180, Springer Science Business Media, Inc. (January 2005)	
	373.	Saulnier, M.G., <i>et al.</i> , "Microwave-assisted synthesis of primary amine HX salts from halides and 7M ammonia in methanol," <i>Tetrahedron Lett.</i> 45:397-399, Elsevier Science Ltd. (January 2004)	
	374.	Schlosser, M. and Geneste, H., "The Organometallic Route to Benzylamine Type Monoamine Oxidase Inhibitors," <i>Tetrahedron</i> 54:10119-10124, Pergamon Press (1998)	
	375.	Schmitt, L., <i>et al.</i> , "Synthesis of Arylalkylmonofluorophosphonates as <i>Myo</i> -Inositol monophosphatase Ligands," <i>Tetrahedron Lett.</i> 39:4009-4012, Elsevier Science Ltd. (1998)	
	376.	Schröder-van der Elst, J.P., <i>et al.</i> , "Effects of 5,5'-diphenylhydantoin on the thyroid status in rats," <i>Eur. J. Endocrinol.</i> 134:221-224, BioScientifica Ltd (1996)	
	377.	Selenkov, H.A. and Asper, Jr., S.P., "Biological Activity of Compounds Structurally Related to Thyroxine," <i>Physiol. Rev.</i> 35:426-474, American Physiological Society (1955)	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	23	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

	378.	Shi, Y., <i>et al.</i> , "Mutant-Selective Thyromimetics for the Chemical Rescue of Thyroid Hormone Receptor Mutants Associated with Resistance to Thyroid Hormone," <i>Biochemistry</i> 44:4612-4626, American Chemical Society (March 2005)	
	379.	Smith, C.L. and O'Malley, B.W., "Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators," <i>Endocrine Rev.</i> 25:45-71, The Endocrine Society (February 2004)	
	380.	Soldin, S.J., <i>et al.</i> , "The measurement of free thyroxine by isotope dilution tandem mass spectrometry," <i>Clinica Chimica Acta</i> 358:113-118, Elsevier Science Ltd. (August 2005)	
	381.	Song, K., <i>et al.</i> , "Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed <i>Cynomolgus</i> monkeys," <i>Atherosclerosis</i> 138:171-182, Elsevier Science Ltd. (1998)	
	382.	Stanton, J.L., <i>et al.</i> , "Synthesis and Biological Activity of Phenoxyphenyl Oxamic Acid Derivatives Related to L-Thyronine," <i>Bioorg. Med. Chem. Lett.</i> 10:1661-1663, Elsevier Science Ltd (2000)	
	383.	Sterling, K. and Brenner, M.A., "Thyroid Hormone Action: Effect of Triiodothyronine on Mitochondrial Adenine Nucleotide Translocase <i>In Vivo</i> and <i>In Vitro</i> ," <i>Metabolism</i> 44:193-199, W.B. Saunders (1995)	
	384.	Tai, S.S.-C., <i>et al.</i> , "Candidate Reference Method for Total Thyroxine in Human Serum: Use of Isotope-Dilution Liquid Chromatography-Mass Spectrometry with Electrospray Ionizaton," <i>Clin. Chem.</i> 48:637-642, American Association For Clinical Chemistry (January 2002)	
	385.	Takayama, S., <i>et al.</i> , "Antithyroid Effects of Propylthiouracil and Sulfamonomethoxine in Rats and Monkeys," <i>Toxicol. Applied Pharmacol.</i> 82:191-199, Academic Press (1986)	
	386.	Tal, D.M. and Karlish, S.J.D., "Synthesis of a Novel Series of Arylmethylisothiuronium Derivatives," <i>Tetrahedron</i> 51:3823-3830, Pergamon Press (1995)	
	387.	Taylor, A.H., <i>et al.</i> , "Beneficial Effects of a Novel Thyromimetic on Lipoprotein Metabolism," <i>Mol. Pharmacol.</i> 52:542-547, American Society for Pharmacology and Experimental Therapeutics (1997)	
	388.	Taylor, S.D., <i>et al.</i> , "Synthesis of Aryl(DifluoromethylenePhosphonates) via Electrophilic Fluorination of α -Carbanions of Benzylic Phosphonates with N-	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	24	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

		Fluorobenzenesulfonimide," <i>Tetrahedron</i> 54:1691-1714, Pergamon Press (1998)	
	389.	Thienpont, L.M., <i>et al.</i> , "Isotope Dilution-Gas Chromatography/Mass Spectrometry and Liquid Chromatography/Electrospray Ionization-Tandem Mass Spectrometry for the Determination of Triiodo-L-Thyronine in Serum," <i>Rapid Commun. Mass Spectrometry</i> 13:1924-1931, John Wiley & Sons, Ltd (1999)	
	390.	Thornber, C.W., "Isosterism and Molecular Modification in Drug Design," <i>Chem. Soc. Rev.</i> 8:563-580, Chemical Society (1979)	
	391.	Togashi, M., <i>et al.</i> , "Conformational adaptation of nuclear receptor ligand binding domains to agonists: Potential for novel approaches to ligand design," <i>J. Steroid Biochem. Mol. Biol.</i> 93:127-137, Elsevier Science Ltd. (February 2005)	
	392.	Tomilov, A.P., <i>et al.</i> , "Electrochemical synthesis of diethyl fluoromethanephosphonate," <i>J. Fluorine Chem.</i> 82:39-41, Elsevier Science Ltd. (1997)	
	393.	Toussaint, O., <i>et al.</i> , "The Copper(I)-Catalyzed Decarboxylation of Malonic Acids: A New Mild and Quantitative Method," <i>Synthesis</i> 1029-1031, Georg Thieme Verlag (1986)	
	394.	Trost, S.U., <i>et al.</i> , "The Thyroid Hormone Receptor- β -Selective Agonist GC-1 Differentially Affects Plasma Lipids and Cardiac Activity," <i>Endocrinology</i> 141:3057-3064, The Endocrine Society (2000)	
	395.	Tsuchimoto, T., <i>et al.</i> , "Scandium(III) Triflate Catalyzed Friedel-Crafts Alkylation Reactions," <i>J. Org. Chem.</i> 62:6997-7005, American Chemical Society (1997)	
	396.	Underwood, A.H., <i>et al.</i> , "A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity," <i>Nature</i> 324:425-429, Nature Publishing Group (1986)	
	397.	Van Rompaey, K., <i>et al.</i> , "A versatile synthesis of 2-substituted 4-amino-1,2,4,5-tetrahydro-2-benzazepine-3-ones," <i>Tetrahedron</i> 59:4421-4432, Pergamon Press (April 2003)	
	398.	Vaughan, M.K., <i>et al.</i> , "Chronic Exposure to Short Photoperiod Inhibits Free Thyroxine Index and Plasma Levels of TSH, T ₄ , Triiodothyronine (T ₃) and Cholesterol in Female Syrian Hamsters," <i>Comp. Biochem. Physiol.</i> 71A:615-618, Pergamon Press Ltd. (1982)	
	399.	Veer, G.V.D.S., <i>et al.</i> , "Temperature Effects on Free-Thyroxine Measurements: Analytical and Clinical Consequences," <i>Clin. Chem.</i> 38:1327-1331, American Association For Clinical Chemistry (1992)	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/580,134
Sheet	25	of	27	Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
				Attorney Docket Number	2358.0080002/RWE/RAS

	400.	Verd, J.C., <i>et al.</i> , "Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits," <i>Br. J. Pharmacol.</i> 127:1479-1485, Nature Publishing Group (1999)	
	401.	Villicev, C.M., <i>et al.</i> , "Thyroid hormone receptor β -specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats," <i>J. Endocrinol.</i> 193:21-29, Society for Endocrinology (January 2007)	
	402.	Visser, T.J., <i>et al.</i> , "Deiodination of Thyroid Hormone by Human Liver," <i>J. Clin. Endocrinol. Metab.</i> 67:17-24, The Endocrine Society (1988)	
	403.	Walker, D.M., <i>et al.</i> , "Design and Synthesis of γ -Oxygenated Phosphinothricins as Inhibitors of Gluamine Synthetase," <i>J. Chem. Soc. Perkin Trans. 1</i> 659-666, Royal Society of Chemistry (1990)	
	404.	Wang, B., <i>et al.</i> , "Effects of triiodo-thyronine on angiotensin-induced cardiomyocyte hypertrophy: reversal of increased β -myosin heavy chain gene expression," <i>Can. J. Physiol. Pharmacol.</i> 84:935-941, NRC Research Press (August 2006)	
	405.	Wang, R., <i>et al.</i> , "Salsalate Administration - A Potential Pharmacological Model of the Sick Euthyroid Syndrome," <i>J. Clin. Endocrinol. Metab.</i> 83:3095-3099, Endocrine Society (1998)	
	406.	Waschbüsch, R., <i>et al.</i> , "A high yielding synthesis of diethyl-1-fluoromethylphosphonate in pure form," <i>C. R. Acad. Sci. Paris, t. I, Série II c</i> 1:49-52, Elsevier Science Ltd. (1998)	
	407.	Wasserscheid, P. and Keim, W., "Ionic Liquids-New "Solutions" for Transition Metal Catalysis," <i>Angew Chem. Int. Ed.</i> 39:3772-3789, Wiley-VCH Verlag GmbH (2000)	
	408.	Webb, P., <i>et al.</i> , "Design of thyroid hormone receptor antagonists from first principles," <i>J. Steroid Biochem. Mol. Biol.</i> 83:59-73, Elsevier Science Ltd. (December 2002)	
	409.	Wechter, W.J., <i>et al.</i> , "Hypocholesterolemic Agents. Thryoalkanols," <i>J. Med. Chem.</i> 8:474-478, American Chemical Society (1965)	
	410.	Wells, P.G., <i>et al.</i> , "Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing," <i>Clin. Pharmacol. Ther.</i> 33:603-608, Nature Publishing Group (1983)	

Examiner Signature	/Rei Tsang Shiao/	Date Considered	
--------------------	-------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)</p>			Complete if Known		
			Application Number	10/580,134	
			Int'l Filing Date	November 19, 2004	
			First Named Inventor	ERION, Mark D.	
			Art Unit	To Be Assigned	
			Examiner Name	To Be Assigned	
Sheet	26	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

411.	Welton, T., "Room-Temperature Ionic Liquids. Solvents for Synthesis and Catalysis," <i>Chem. Rev.</i> 99:2071-2083, American Chemical Society (1999)
412.	Wibom, R., <i>et al.</i> , "A sensitive method for measuring ATP-formation in rat muscle mitochondria," <i>Scand. J. Clin. Lab. Invest.</i> 50:143-152, Taylor & Francis Health Sciences (1990)
413.	Wienand, A., <i>et al.</i> , "Design, Synthesis and Biological Evaluation of Selective Boron-containing Thrombin Inhibitors," <i>Bioorg. Med. Chem.</i> 7:1295-1307, Elsevier Science Ltd. (1999)
414.	Willnow, T.E. and Herz, J., "Animal models for disorders of hepatic lipoprotein metabolism," <i>J. Mol. Med.</i> 73:213-220, Springer-Verlag (1995)
415.	Winder, W.W., <i>et al.</i> , "Effects of thyroid hormone administration on skeletal muscle mitochondria," <i>Am. J. Physiol.</i> 228:1341-1345, American Physiological Society (1975)
416.	Wondisford, F.E., "Unlikely partners in weight loss?," <i>Cell Metab.</i> 3:81-82, Cell Press (February 2006)
417.	Wu, K.-M. and Farrelly, J.G., "Preclinical Development of New Drugs that Enhance Thyroid Hormone Metabolism and Clearance: Inadequacy of Using Rats as an Animal Model for Predicting Human Risks in an IND and NDA," <i>Am. J. Therap.</i> 13:141-144, Lippincott Williams & Wilkins (March/April 2006)
418.	Wu, Y., <i>et al.</i> , "Removal of Thiazolidinethione Auxiliaries with Benzyl Alcohol Mediated by DMAP," <i>J. Org. Chem.</i> 69:6141-6144, American Chemical Society (May 2004)
419.	Xu, L., <i>et al.</i> , "Heck Reaction in Ionic Liquids and the in Situ Identification of N-Heterocyclic Carbene Complexes of Palladium," <i>Organometallics</i> 19:1123-1127, American Chemical Society (2000)
420.	Yang, W., <i>et al.</i> , "Boronic Acid Compounds as Potential Pharmaceutical Agents," <i>Med. Res. Rev.</i> 23:346-368, Wiley Periodicals, Inc. (May 2003)
421.	Yang, C. and Pittman, Jr., C.U., "Reductions of Organic Functional Groups Using NaBH ₄ or NaBH ₄ /LiCl in Diglyme at 125 to 162 °C," <i>Synth. Commun.</i> 28:2027-2041, Georg Thieme Verlag (1998)
422.	Ye, L., <i>et al.</i> , "Thyroid Receptor Ligands. 1. Agonist Ligands Selective for the Thyroid Receptor β1," <i>J. Med. Chem.</i> 46:1580-1588, American Chemical Society (March 2003)

Examiner Signature	/Rei Tsang Shiao/	Date Considered
--------------------	-------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/580,134
				Int'l Filing Date	November 19, 2004
				First Named Inventor	ERION, Mark D.
				Art Unit	To Be Assigned 1626
				Examiner Name	To Be Assigned Reitsang Shiao
Sheet	27	of	27	Attorney Docket Number	2358.0080002/RWE/RAS

	423.	Yen, P.M., "Physiological and Molecular Basis of Thyroid Hormone Action," <i>Physiol. Rev.</i> 81:1097-1142, American Physiological Society (2001)	
	424.	Yoshihara, H.A.I., <i>et al.</i> , "Structural Determinants of Selective Thyromimetics" <i>J. Med. Chem.</i> 46:3152-3161, American Chemical Society (July 2003)	
	425.	Yoshioka, R., <i>et al.</i> , "The Optical Resolution and Asymmetric Transformation of DL-p-Hydroxyphenylglycine with (+)-1-Phenylethanesulfonic Acid," <i>Bull. Chem. Soc. Jpn.</i> 60:649-652, The Chemical Society of Japan (1987)	
	426.	Yu, K.-L., <i>et al.</i> , "Concerning the Phosphorylation of Vicinal Diols," <i>Synth. Commun.</i> 18:465-468, Taylor & Francis, Inc. (1988)	
	427.	Zalkow, L.H., <i>et al.</i> , "Studies in the Synthesis of Camptothecin. An Efficient Synthesis of 2,3-Dihydro-1 <i>H</i> -pyrrolo[3,4- <i>b</i>]quinoline," <i>J. Chem. Soc.</i> 3551-3554, Royal Society of Chemistry (1971)	
	428.	Zenker, N. and Jorgensen, E.C., "Thyroxine Analogs. I. Synthesis of 3,5-Diiodo-4-(2'-alkylphenoxy)-DL-phenylalanines," <i>J. Am. Chem. Soc.</i> 81:4643-4647, American Chemical Society (1959)	
	429.	Zhang, N. and Casida, J.E., "Novel Irreversible Butyrylcholinesterase Inhibitors: 2-Chloro-1-(substituted-phenyl)ethylphosphonic Acids," <i>Bioorg. Med. Chem.</i> 10:1281-1290, Elsevier Science Ltd. (November 2002)	
	430.	Zhang, J. and Lazar, M.A., "The Mechanism of Action of Thyroid Hormones," <i>Annu. Rev. Physiol.</i> 62:439-466, Annual Reviews (2000)	

706260v1

Examiner Signature	/Rei Tsang Shiao/	Date Considered	7/27/09
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./